Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2011-12

AUTHORS

Amit Agrawal, John FR Robertson, KL Cheung

ABSTRACT

BACKGROUND: It has been shown in in-vitro experiments that "withdrawal" of tamoxifen inhibits growth of tumor cells. However, evidence is scarce when this is extrapolated into clinical context. We report our experience to verify the clinical relevance of "withdrawal therapy". METHODS: Breast cancer patients since 1998 who fulfilled the following criteria were selected from the departmental database and the case-notes were retrospectively reviewed: (1) estrogen receptor positive, operable primary breast cancer in elderly (age > 70 years), locally advanced or metastatic breast cancer; (2) disease deemed suitable for treatment by hormonal manipulation; (3) disease assessable by UICC criteria; (4) received "withdrawal" from a prior endocrine agent as a form of therapy; (5) on "withdrawal therapy" for ≥ 6 months unless they progressed prior. RESULTS: Seventeen patients with median age of 84.3 (53.7-92.5) had "withdrawal therapy" as second to tenth line of treatment following prior endocrine therapy using tamoxifen (n = 10), an aromatase inhibitor (n = 5), megestrol acetate (n = 1) or fulvestrant (n = 1). Ten patients (58.8%) had clinical benefit (CB) (complete response/partial response/stable disease ≥ 6 months) with a median duration of Clinical Benefit (DoCB) of 10+ (7-27) months. Two patients remain on "withdrawal therapy" at the time of analysis. CONCLUSION: "Withdrawal therapy" appears to produce sustained CB in a significant proportion of patients. This applies not only to "withdrawal" from tamoxifen, but also from other categories of endocrine agents. "Withdrawal" from endocrine therapy is, therefore, a viable intercalating option between endocrine agents to minimise resistance and provide additional line of therapy. It should be considered as part of the sequencing of endocrine therapy. More... »

PAGES

101

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1477-7819-9-101

DOI

http://dx.doi.org/10.1186/1477-7819-9-101

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1029016766

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21906312


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estrogen Receptor Modulators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Derby Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413619.8", 
          "name": [
            "Division of Breast Surgery, GEM School, University of Nottingham, Royal Derby Hospital, DE22 3NE, Derby, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agrawal", 
        "givenName": "Amit", 
        "id": "sg:person.01036236301.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036236301.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Derby Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413619.8", 
          "name": [
            "Division of Breast Surgery, GEM School, University of Nottingham, Royal Derby Hospital, DE22 3NE, Derby, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "John FR", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Derby Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413619.8", 
          "name": [
            "Division of Breast Surgery, GEM School, University of Nottingham, Royal Derby Hospital, DE22 3NE, Derby, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheung", 
        "givenName": "KL", 
        "id": "sg:person.016477423232.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016477423232.32"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(74)91364-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006753414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011360956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.1989.00390020139030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016751119"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(87)90717-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020309835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(87)90717-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020309835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7819-4-44", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033917230", 
          "https://doi.org/10.1186/1477-7819-4-44"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jso.2930220112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036953442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jsbmb.2004.12.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050101750"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.149.2.449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054112355"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.80.10.7559875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064319145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a058286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076569095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077005601", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078441831", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078637710", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079729309", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/73.2.313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1081843227"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-12", 
    "datePublishedReg": "2011-12-01", 
    "description": "BACKGROUND: It has been shown in in-vitro experiments that \"withdrawal\" of tamoxifen inhibits growth of tumor cells. However, evidence is scarce when this is extrapolated into clinical context. We report our experience to verify the clinical relevance of \"withdrawal therapy\".\nMETHODS: Breast cancer patients since 1998 who fulfilled the following criteria were selected from the departmental database and the case-notes were retrospectively reviewed: (1) estrogen receptor positive, operable primary breast cancer in elderly (age > 70 years), locally advanced or metastatic breast cancer; (2) disease deemed suitable for treatment by hormonal manipulation; (3) disease assessable by UICC criteria; (4) received \"withdrawal\" from a prior endocrine agent as a form of therapy; (5) on \"withdrawal therapy\" for \u2265 6 months unless they progressed prior.\nRESULTS: Seventeen patients with median age of 84.3 (53.7-92.5) had \"withdrawal therapy\" as second to tenth line of treatment following prior endocrine therapy using tamoxifen (n = 10), an aromatase inhibitor (n = 5), megestrol acetate (n = 1) or fulvestrant (n = 1). Ten patients (58.8%) had clinical benefit (CB) (complete response/partial response/stable disease \u2265 6 months) with a median duration of Clinical Benefit (DoCB) of 10+ (7-27) months. Two patients remain on \"withdrawal therapy\" at the time of analysis.\nCONCLUSION: \"Withdrawal therapy\" appears to produce sustained CB in a significant proportion of patients. This applies not only to \"withdrawal\" from tamoxifen, but also from other categories of endocrine agents. \"Withdrawal\" from endocrine therapy is, therefore, a viable intercalating option between endocrine agents to minimise resistance and provide additional line of therapy. It should be considered as part of the sequencing of endocrine therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1477-7819-9-101", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032056", 
        "issn": [
          "1477-7819"
        ], 
        "name": "World Journal of Surgical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Clinical relevance of \"withdrawal therapy\" as a form of hormonal manipulation for breast cancer", 
    "pagination": "101", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8a3adad0f7bb996bc3b62fe2bf81937dc8c90179cef8ec5990044d02d112f7cc"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21906312"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101170544"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1477-7819-9-101"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1029016766"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1477-7819-9-101", 
      "https://app.dimensions.ai/details/publication/pub.1029016766"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000550.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1477-7819-9-101"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-9-101'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-9-101'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-9-101'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-9-101'


 

This table displays all metadata directly associated to this object as RDF triples.

184 TRIPLES      21 PREDICATES      59 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1477-7819-9-101 schema:about N0efd526201b541e3932183323a1b3bba
2 N135e0fd0a429433ea9c130c7644007af
3 N1f1c7d118fd045deb05730fe7c2fa20d
4 N3de400f3be7d43659e332d6fc8a2a3d9
5 N46df301adf344f4685d2512290902005
6 N5b6b33da447a46bf95b24e56760f41a7
7 N8b1b604345064b6f9231f91ef1cf9389
8 N90f543774e014856a3a6eb572d26db25
9 N91b116188dde4fefad56853b33331f3d
10 N91bc31387f624242855574eedd1646ba
11 N96222517287b4c43a52b0ce374cba08e
12 Nb4aaeb8c141240a396a5a8177e43a62e
13 Nc9b25b70e24147909e5258d7d2d49747
14 Ne45be0e16a0a47b6a0f41698a13b887a
15 Nfe786cc4a7e34f3e84e911a9ebaf1e3b
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N709ac23261124022af87ca4bf53b14e0
19 schema:citation sg:pub.10.1186/1477-7819-4-44
20 https://app.dimensions.ai/details/publication/pub.1077005601
21 https://app.dimensions.ai/details/publication/pub.1078441831
22 https://app.dimensions.ai/details/publication/pub.1078637710
23 https://app.dimensions.ai/details/publication/pub.1079729309
24 https://doi.org/10.1001/archinte.149.2.449
25 https://doi.org/10.1001/archinte.1989.00390020139030
26 https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f
27 https://doi.org/10.1002/jso.2930220112
28 https://doi.org/10.1016/j.jsbmb.2004.12.005
29 https://doi.org/10.1016/s0140-6736(74)91364-6
30 https://doi.org/10.1016/s0140-6736(87)90717-3
31 https://doi.org/10.1093/jnci/73.2.313
32 https://doi.org/10.1093/oxfordjournals.annonc.a058286
33 https://doi.org/10.1210/jcem.80.10.7559875
34 schema:datePublished 2011-12
35 schema:datePublishedReg 2011-12-01
36 schema:description BACKGROUND: It has been shown in in-vitro experiments that "withdrawal" of tamoxifen inhibits growth of tumor cells. However, evidence is scarce when this is extrapolated into clinical context. We report our experience to verify the clinical relevance of "withdrawal therapy". METHODS: Breast cancer patients since 1998 who fulfilled the following criteria were selected from the departmental database and the case-notes were retrospectively reviewed: (1) estrogen receptor positive, operable primary breast cancer in elderly (age > 70 years), locally advanced or metastatic breast cancer; (2) disease deemed suitable for treatment by hormonal manipulation; (3) disease assessable by UICC criteria; (4) received "withdrawal" from a prior endocrine agent as a form of therapy; (5) on "withdrawal therapy" for ≥ 6 months unless they progressed prior. RESULTS: Seventeen patients with median age of 84.3 (53.7-92.5) had "withdrawal therapy" as second to tenth line of treatment following prior endocrine therapy using tamoxifen (n = 10), an aromatase inhibitor (n = 5), megestrol acetate (n = 1) or fulvestrant (n = 1). Ten patients (58.8%) had clinical benefit (CB) (complete response/partial response/stable disease ≥ 6 months) with a median duration of Clinical Benefit (DoCB) of 10+ (7-27) months. Two patients remain on "withdrawal therapy" at the time of analysis. CONCLUSION: "Withdrawal therapy" appears to produce sustained CB in a significant proportion of patients. This applies not only to "withdrawal" from tamoxifen, but also from other categories of endocrine agents. "Withdrawal" from endocrine therapy is, therefore, a viable intercalating option between endocrine agents to minimise resistance and provide additional line of therapy. It should be considered as part of the sequencing of endocrine therapy.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree true
40 schema:isPartOf N0a7b0ea9fb044ca5a85ea2ea8dd4c6fb
41 N5b853bf6e4194ecfb7a82ef20b1ccb2d
42 sg:journal.1032056
43 schema:name Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer
44 schema:pagination 101
45 schema:productId N46802a69ec43430b9b284c3992221947
46 N61f32150b7824c528635d459e0f07ed0
47 Ncb6cadb218624447a5d5cabef0be75ea
48 Ncc9dfc3f7bac42608725de09dccf0afa
49 Ne0d497c2ef5643c784faac057402337b
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029016766
51 https://doi.org/10.1186/1477-7819-9-101
52 schema:sdDatePublished 2019-04-10T18:26
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher Ne011ffb7cd58455ba354b24bcaecb836
55 schema:url http://link.springer.com/10.1186%2F1477-7819-9-101
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N0a7b0ea9fb044ca5a85ea2ea8dd4c6fb schema:issueNumber 1
60 rdf:type schema:PublicationIssue
61 N0efd526201b541e3932183323a1b3bba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Middle Aged
63 rdf:type schema:DefinedTerm
64 N135e0fd0a429433ea9c130c7644007af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Tamoxifen
66 rdf:type schema:DefinedTerm
67 N1f1c7d118fd045deb05730fe7c2fa20d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Antineoplastic Agents, Hormonal
69 rdf:type schema:DefinedTerm
70 N3de400f3be7d43659e332d6fc8a2a3d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Estrogen Receptor Modulators
72 rdf:type schema:DefinedTerm
73 N46802a69ec43430b9b284c3992221947 schema:name dimensions_id
74 schema:value pub.1029016766
75 rdf:type schema:PropertyValue
76 N46df301adf344f4685d2512290902005 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Treatment Outcome
78 rdf:type schema:DefinedTerm
79 N5b6b33da447a46bf95b24e56760f41a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Receptors, Estrogen
81 rdf:type schema:DefinedTerm
82 N5b853bf6e4194ecfb7a82ef20b1ccb2d schema:volumeNumber 9
83 rdf:type schema:PublicationVolume
84 N5d6e451a8b2c4341a43ad8f06f37b176 rdf:first sg:person.016477423232.32
85 rdf:rest rdf:nil
86 N61f32150b7824c528635d459e0f07ed0 schema:name nlm_unique_id
87 schema:value 101170544
88 rdf:type schema:PropertyValue
89 N709ac23261124022af87ca4bf53b14e0 rdf:first sg:person.01036236301.85
90 rdf:rest N73e972bdf1b14eb0a20ce8326232ab76
91 N73e972bdf1b14eb0a20ce8326232ab76 rdf:first sg:person.07764637207.20
92 rdf:rest N5d6e451a8b2c4341a43ad8f06f37b176
93 N8b1b604345064b6f9231f91ef1cf9389 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Humans
95 rdf:type schema:DefinedTerm
96 N90f543774e014856a3a6eb572d26db25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Salvage Therapy
98 rdf:type schema:DefinedTerm
99 N91b116188dde4fefad56853b33331f3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Female
101 rdf:type schema:DefinedTerm
102 N91bc31387f624242855574eedd1646ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Retrospective Studies
104 rdf:type schema:DefinedTerm
105 N96222517287b4c43a52b0ce374cba08e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Drug Resistance, Neoplasm
107 rdf:type schema:DefinedTerm
108 Nb4aaeb8c141240a396a5a8177e43a62e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Breast Neoplasms
110 rdf:type schema:DefinedTerm
111 Nc9b25b70e24147909e5258d7d2d49747 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Follow-Up Studies
113 rdf:type schema:DefinedTerm
114 Ncb6cadb218624447a5d5cabef0be75ea schema:name doi
115 schema:value 10.1186/1477-7819-9-101
116 rdf:type schema:PropertyValue
117 Ncc9dfc3f7bac42608725de09dccf0afa schema:name pubmed_id
118 schema:value 21906312
119 rdf:type schema:PropertyValue
120 Ne011ffb7cd58455ba354b24bcaecb836 schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 Ne0d497c2ef5643c784faac057402337b schema:name readcube_id
123 schema:value 8a3adad0f7bb996bc3b62fe2bf81937dc8c90179cef8ec5990044d02d112f7cc
124 rdf:type schema:PropertyValue
125 Ne45be0e16a0a47b6a0f41698a13b887a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Aged, 80 and over
127 rdf:type schema:DefinedTerm
128 Nfe786cc4a7e34f3e84e911a9ebaf1e3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Aged
130 rdf:type schema:DefinedTerm
131 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
132 schema:name Medical and Health Sciences
133 rdf:type schema:DefinedTerm
134 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
135 schema:name Oncology and Carcinogenesis
136 rdf:type schema:DefinedTerm
137 sg:journal.1032056 schema:issn 1477-7819
138 schema:name World Journal of Surgical Oncology
139 rdf:type schema:Periodical
140 sg:person.01036236301.85 schema:affiliation https://www.grid.ac/institutes/grid.413619.8
141 schema:familyName Agrawal
142 schema:givenName Amit
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036236301.85
144 rdf:type schema:Person
145 sg:person.016477423232.32 schema:affiliation https://www.grid.ac/institutes/grid.413619.8
146 schema:familyName Cheung
147 schema:givenName KL
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016477423232.32
149 rdf:type schema:Person
150 sg:person.07764637207.20 schema:affiliation https://www.grid.ac/institutes/grid.413619.8
151 schema:familyName Robertson
152 schema:givenName John FR
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
154 rdf:type schema:Person
155 sg:pub.10.1186/1477-7819-4-44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033917230
156 https://doi.org/10.1186/1477-7819-4-44
157 rdf:type schema:CreativeWork
158 https://app.dimensions.ai/details/publication/pub.1077005601 schema:CreativeWork
159 https://app.dimensions.ai/details/publication/pub.1078441831 schema:CreativeWork
160 https://app.dimensions.ai/details/publication/pub.1078637710 schema:CreativeWork
161 https://app.dimensions.ai/details/publication/pub.1079729309 schema:CreativeWork
162 https://doi.org/10.1001/archinte.149.2.449 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054112355
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1001/archinte.1989.00390020139030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016751119
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f schema:sameAs https://app.dimensions.ai/details/publication/pub.1011360956
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1002/jso.2930220112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036953442
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/j.jsbmb.2004.12.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050101750
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1016/s0140-6736(74)91364-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006753414
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s0140-6736(87)90717-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020309835
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1093/jnci/73.2.313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081843227
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1093/oxfordjournals.annonc.a058286 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076569095
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1210/jcem.80.10.7559875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064319145
181 rdf:type schema:CreativeWork
182 https://www.grid.ac/institutes/grid.413619.8 schema:alternateName Royal Derby Hospital
183 schema:name Division of Breast Surgery, GEM School, University of Nottingham, Royal Derby Hospital, DE22 3NE, Derby, UK
184 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...